EPS for Ascendis Pharma A/S (ASND) Expected At $-0.93 on May, 22

May 16, 2018 - By Darrin Badillo

On May, 22. Investors wait Ascendis Pharma A/S (NASDAQ:ASND) to publish its quarterly earnings, Zacks reports. Analysts forecast $-0.93 EPS, which is $0.10 down or 12.05 % from 2017’s $-0.83 EPS. -13.89 % EPS growth is what analysts predict. $-1.08 EPS was published for last quarter. The stock increased 1.49% or $0.97 during the last trading session, hitting $66.14.Ascendis Pharma A/S has volume of 72,462 shares. Since May 16, 2017 ASND has risen 130.09% and is uptrending. ASND outperformed the S&P500 by 118.54%.

Ascendis Pharma A/S (NASDAQ:ASND) Ratings Coverage

In total 4 analysts cover Ascendis Pharma A\/S (NASDAQ:ASND). “Buy” rating has 4, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 12 are the (NASDAQ:ASND)’s analyst reports since November 17, 2017 according to StockzIntelligence Inc. On Monday, May 14 the company was maintained by J.P. Morgan. On Tuesday, February 6 the stock of Ascendis Pharma A/S (NASDAQ:ASND) earned “Buy” rating by Wedbush. On Thursday, January 25 Bank of America maintained Ascendis Pharma A/S (NASDAQ:ASND) with “Buy” rating. On Monday, March 19 the rating was maintained by Wedbush with “Buy”. In Friday, November 17 report Bank of America maintained it with “Buy” rating and $43 target. On Monday, February 26 the stock of Ascendis Pharma A/S (NASDAQ:ASND) has “Buy” rating given by Wedbush. On Wednesday, April 4 the firm has “Buy” rating given by Wedbush. On Wednesday, January 17 the stock of Ascendis Pharma A/S (NASDAQ:ASND) earned “Buy” rating by J.P. Morgan. On Friday, January 5 Wedbush maintained Ascendis Pharma A/S (NASDAQ:ASND) rating. Wedbush has “Buy” rating and $62.0 target. The company rating was maintained by Credit Suisse on Thursday, February 22.

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs.The company has $2.75 billion market cap. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries.Last it reported negative earnings. The firm is also developing TransCon Peptides for the treatment of diabetes; TransCon ranibizumab, a compound to support injection of ranibizumab in ophthalmology; TransCon parathyroid hormone for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

More recent Ascendis Pharma A/S (NASDAQ:ASND) news were posted by Benzinga.com, Nasdaq.com and Globenewswire.com. The first one has “Top Ideas From The 2018 Sohn Conference: Box, Bitcoin, Facebook, Palo Alto And More” as a title and was posted on April 23, 2018. The next is “Ascendis Pharma A/S Announces Dosing of First Subjects in Phase 1 Trial of TransCon CNP” on May 08, 2018. And last was posted on April 25, 2018, called “Ascendis Pharma A/S Announces Upcoming Investor Presentations”.

Ascendis Pharma A/S (NASDAQ:ASND) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.